8-K: Orgenesis Issues Warrants to Alpha Prosperity Fund

Orgenesis Inc. has issued 3.29 million non-transferable warrants to Alpha Prosperity Fund SPC as part of a previously disclosed convertible loan agreement.

Summary

• Orgenesis Inc. issued 3,289,490 non-transferable warrants to Alpha Prosperity Fund SPC on January 9, 2026.
• The warrants are exercisable for 3,289,490 shares of the company's common stock at an exercise price of US $0.076 per share.
• The aggregate exercise price for these warrants is $250,000.
• These warrants will expire and become null and void at 5:00 P.M. (Pacific Time) on January 9, 2029.
• The issuance is related to the first $1,000,000 drawdown under a Convertible Loan Agreement dated September 10, 2025, which includes a $1,000,000 convertible loan and a $10,000,000 credit facility.
• The warrants and the underlying shares have not been registered under the 1933 Act or any U.S. state securities laws, issued in an offshore transaction to non-U.S. persons pursuant to Regulation S, and are exempt from registration under Section 4(a)(2) of the Securities Act.

Sentiment

Score: 4

Explanation: The filing represents an expected step in a previously announced financing, which is a necessary action for the company. However, the context of the company's trading on the OTC Expert Market and the restrictions on the warrants introduce significant negative sentiment and risk, outweighing the positive aspect of securing financing.

Positives

• The issuance of warrants is a component of a financing agreement, indicating a structured approach to securing capital for the company.
• The underlying Convertible Loan Agreement provides access to a $1,000,000 convertible loan and a $10,000,000 credit facility, enhancing the company's liquidity options.

Negatives

• The company's common stock was delisted from Nasdaq on October 17, 2024, and subsequently moved to the OTCQX, then Pink Limited, and finally to the OTC Expert Market tier by July 29, 2025, indicating significant operational or financial challenges.
• The warrants are explicitly labeled as 'NON-TRANSFERABLE' on the certificate, which may limit the holder's liquidity and flexibility, although the terms and conditions state they are transferable under certain conditions.
• The securities are restricted from being offered or sold in the United States or to U.S. persons unless registered or an exemption applies, limiting the potential investor base.

Risks

• Potential for dilution of existing shareholders if the 3,289,490 warrants are exercised.
• The company's stock trading on the OTC Expert Market tier implies lower liquidity, transparency, and potentially higher volatility compared to major exchanges.
• Ambiguity exists regarding the transferability of the warrants; the certificate states 'NON-TRANSFERABLE', while the attached terms and conditions state they are 'transferable at the discretion of warrant holder provided that such transfer does not contravene any law'.
• The restrictions on offering or selling these securities in the U.S. or to U.S. persons could impact future capital raising efforts or the market for these specific warrants.

Future Outlook

The warrants provide a potential future capital inflow for Orgenesis Inc. if exercised by January 9, 2029. The underlying Convertible Loan Agreement and credit facility indicate ongoing financing activities and potential future drawdowns, which could support the company's operations and strategic initiatives.

Management Comments

• Vered Caplan, Chief Executive Officer, signed the 8-K report on behalf of Orgenesis Inc.

Industry Context

The company's delisting from Nasdaq and subsequent trading on the OTC Expert Market tier places it in a segment typically associated with higher risk, lower liquidity, and reduced investor visibility compared to companies listed on major exchanges. This move often reflects challenges in meeting listing standards or maintaining investor confidence, contrasting with broader industry trends for established public companies.

Comparison to Industry Standards

• The company's delisting from Nasdaq and subsequent trading on the OTC Expert Market tier is a significant deviation from the industry standard for publicly traded companies, which typically aim for listing on major exchanges like Nasdaq or NYSE to ensure liquidity, transparency, and access to a broader investor base.
• Companies on the OTC Expert Market often face challenges in attracting institutional investment and maintaining a robust share price due to limited public information and trading restrictions, unlike peers on regulated exchanges.

Corporate Governance

Related Party Transactions

• The issuance of warrants to Alpha Prosperity Fund SPC is part of a Convertible Loan Agreement where Alpha Prosperity Fund SPC acts as the Lender, establishing a related party transaction in the context of financing.

Stakeholder Impact

• Shareholders face potential dilution from the exercise of the 3,289,490 warrants, which could increase the total number of outstanding shares.
• The company benefits from the potential future capital infusion upon warrant exercise and the ongoing financing provided by the Convertible Loan Agreement, which can support operations and strategic growth.
• The warrant holder, Alpha Prosperity Fund SPC, gains the right to acquire company stock at a fixed price, offering potential upside if the stock price increases, while also being subject to restrictions on transferability and sale to U.S. persons.

Next Steps

• The warrant holder, Alpha Prosperity Fund SPC, may exercise the warrants to purchase shares of common stock at any time until January 9, 2029.
• Orgenesis Inc. may proceed with further drawdowns under the $10,000,000 credit facility, each potentially triggering the issuance of additional warrants.

Key Dates

Recommendation

The filing details the execution of a warrant issuance as part of a previously disclosed convertible loan agreement, which provides a financing mechanism for the company. While securing financing is generally positive, the company's current trading status on the OTC Expert Market and the non-transferable nature of the warrants (as stated on the certificate) indicate significant underlying challenges and limited liquidity. Investors should hold, awaiting further operational and financial performance updates, while acknowledging the high-risk profile associated with the company's market tier and financing structure.

Keywords

Orgenesis Inc., ORGS, Warrants, Convertible Loan, Alpha Prosperity Fund, Regulation S, Offshore Transaction, SEC Filing, 8-K, Equity Financing, OTC Expert Market, Dilution